BRAF and colorectal carcinoma: The prospective and observational BRiTE study indicated that bevacizumab continuation dramatically improved the OS of patients with CRC (31.8 vs. 19.9 months, HR = 0.48, p < 0.001) in comparison with no maintenance.196 Continuation of CAP and bevacizumab significantly prolonged the progression time in patients after first-line XELOX plus bevacizumab compared with observation (11.7 vs. 8.5 months, HR = 0.67, p < 0.0001)186 regardless of RAS/BRAF mutation status and mismatch repair (MMR) status.197